Being-similar: From benchside to bedside

Manish Mahajan
Lupin Ltd., India

Biosimilars has been the topic of contention, enthusiasm and research for the past couple decades both to the industry and regulatory authorities. With the introduction of latest technology at -omics front, one could expect further deliberations in not only easy lead identification and therapeutic targets but also growing interest in biopharmaceutical companies to harness this opportunity in discovering the bio-betters or similars. Although we still debate upon the regulatory challenges of whether the innovator product and its similar is replaceable or not, there lies a bigger uncertainty at the place of its advocator i.e., the physician. Various surveys have demonstrated that physician have little clue about biosimilars and still apprehensive about its quality and safety. This behavior is not in sync with the current policy of low income countries where public health is not only a state affair but also with a limited budget. The onus is not only on the industry but also on the other stake holders to justify the very purpose of “Being-Similar”.

Biography
Manish Mahajan has completed his MD from All India Institute of Medical Sciences, New Delhi in Biophysics; and holds a Post Graduate Diploma in Pharmaceutical Marketing. He has published various papers in reputed national and international journals and serving as a member of reviewer panel of a reputed journal. He is a senior medical advisor of Lupin Limited and heads all the medico-marketing activities for India region. His areas of expertise and interests are Therapeutic Lead and Target Identification; Biosimilar Pre and Clinical development, Medico- Marketing and Regulatory Affairs.

dr.manish007@gmail.com